Therapeutics: Nuclear receptor subfamily 2 group F member 6 (NR2F6; COUP-TFIII)

Mouse studies suggest inhibiting NR2F6 could help treat cancer. In a transgenic mouse model of prostate cancer, NR2F6 knockout increased tumor infiltration by CD4+ and CD8+ T cells expressing interleu...